Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Robbins WendyeOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,925Price:$7.58
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Gray Mary AnnOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,574Price:$7.58
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Rieflin William JlOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,871Price:$7.58
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Ho WilliamOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Young Rodney KBOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Wong Brian RussellOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-898Price:$22.78
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,000Price:--
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,000Price:$6.18
Filings by filing date
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Robbins WendyeOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,925Price:$7.58
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Gray Mary AnnOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,574Price:$7.58
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Rieflin William JlOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,871Price:$7.58
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Ho WilliamOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Young Rodney KBOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Jan 31, 2024 (filed on Feb 01, 2024)Insider Name:Wong Brian RussellOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-898Price:$22.78
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,000Price:--
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Brockstedt Dirk G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,000Price:$6.18
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 561 Eccles Ave SOUTH SAN FRANCISCO CA 94080-1906 |
Tel: | N/A |
Website: | https://rapt.com |
IR: | See website |
Key People | ||
Brian Wong President, Chief Executive Officer, Director | Rodney K. B. Young Chief Financial Officer | Dirk Brockstedt Chief Scientific Officer |
Michael Listgarten General Counsel | William Ho Chief Medical Officer |
Business Overview |
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors. |
Financial Overview |
For the fiscal year ended 31 December 2023, Rapt Therapeutics Inc revenues decreased from $1.5M to $0K. Net loss increased 39% to $116.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 50% to $93.1M (expense), Stock-based Compensation in SGA increase of 51% to $9.2M (expense). |
Employees: | 131 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $120.93M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$125.81M as of Dec 31, 2023 |
Net annual income (TTM): | -$116.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$98.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 34,799,702 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |